• A Ruggeri, R Peffault de Latour, M Carmagnat, E Clave, C Douay, J Larghero, J-M Cayuela, R Traineau, M Robin, A Madureira, P Ribaud, C Ferry, A Devergie, D Purtill, C Rabian, E Gluckman, A Toubert, G Socié, and V Rocha.
• Service d'Hématologie-Greffe, Hôpital Saint Louis, APHP, Paris University 7, Paris, France.
• Transpl Infect Dis. 2011 Oct 1; 13 (5): 456-65.

AbstractDouble unrelated cord blood transplant (dUCBT) has been used to circumvent cell dose limitation of single UCBT; however, few data are available describing outcomes, infectious disease, and immune recovery. We analyzed 35 consecutive dUCBT recipients with high-risk malignant disorders (n=21) and bone marrow failure syndromes (n=14). Median follow-up was 32 months. Conditioning regimen was myeloablative in 14 and reduced intensity in 21 patients. Median infused nucleated cell dose was 4 × 10(7) /kg. Median time to absolute neutrophil count >0.5 × 10(9) /L was 25 days. Cumulative incidence (CI) of acute grade II-IV graft-versus-host disease was 47%. Estimated overall survival at 2 years was 48%. CI of first viral infections at 1 year was 92%. We observed 49 viral infections in 30 patients, 34 bacterial infections in 19 patients, and 16 fungal or parasitic infections in 12 patients. Lymphocyte subset analyses were performed at 3, 6, 9, and >12 months after dUCBT. Decreased T-cell and B-cell counts with expansion of natural killer cells were observed until 9 months post transplantation. Recovery of thymopoiesis measured by T-cell receptor excision circles was impaired until 9 months after dUCBT, when the appearance of new thymic precursors was observed. Delayed immune recovery and high incidence of infectious complications were observed after dUCBT in patients with high-risk hematological diseases.© 2011 John Wiley & Sons A/S.

30 keywords...

hide…